phosphonoacetic acid has been researched along with Soft Tissue Neoplasms in 5 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "A total of 21 patients with advanced soft tissue sarcoma enrolled in a phase II trial of 3." | 6.67 | A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma. ( Baselga, J; Casper, ES; Magill, GB; Markman, M; Ranhosky, A; Smart, TB, 1991) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "A total of 21 patients with advanced soft tissue sarcoma enrolled in a phase II trial of 3." | 2.67 | A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma. ( Baselga, J; Casper, ES; Magill, GB; Markman, M; Ranhosky, A; Smart, TB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bramwell, V | 1 |
| Van Oosterom, A | 1 |
| Mouridsen, HT | 1 |
| Cheix, F | 1 |
| Somers, R | 1 |
| Thomas, D | 2 |
| Rozencweig, M | 2 |
| Kleeberg, UR | 1 |
| Mulder, JH | 1 |
| Rümke, P | 1 |
| Kurzrock, R | 1 |
| Yap, BS | 1 |
| Plager, C | 1 |
| Papdopoulos, N | 1 |
| Benjamin, RS | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Casper, ES | 1 |
| Baselga, J | 1 |
| Smart, TB | 1 |
| Magill, GB | 1 |
| Markman, M | 1 |
| Ranhosky, A | 1 |
| Morton, RF | 1 |
| Creagan, ET | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
2 trials available for phosphonoacetic acid and Soft Tissue Neoplasms
| Article | Year |
|---|---|
A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Dipyridamole; Drug Evaluation; Drug Therapy, Comb | 1991 |
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
3 other studies available for phosphonoacetic acid and Soft Tissue Neoplasms
| Article | Year |
|---|---|
N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Digestive System; Drug Erup | 1982 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Eruptions; Drug Evaluation; Female; Humans; | 1982 |
Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Bone Neoplasms; Diarrhea; Drug Evaluati | 1984 |